INMEGEN take parts in International Consortium of Cancer Genome


Mexico City / July13, 2011

From July 10 to July 13, 2011 it took place in Kyoto City, Japan, the 5th International Consortium Cancer Genome scientific meeting (ICGC, for its acronym in English) which was attended by over 400 researchers around the world, all of them dedicated to genomic analysis of various types of human tumors.

International Consortium Cancer Genome was created with the aim to coordinate international projects focused on the genetic structure changes analysis in a variety of cancers, especially those that contribute to the greatest number of  worldwide deaths. Consortium objective is to complete the whole genome analysis of 25,000 tumors in order to develop a public catalog of the most  genetic alterations presents in human tumors.

As part of this event, on July 12 it was presented the work results: “Genomic analysis in breast cancer”. This project is part of  Slim Initiative for Genomic Medicine, which is coordinated and funded by Carlos Slim Intitute Health and where works National Institute of Genomic Medicine (INMEGEN) in Mexico and Broad Institute of MIT and Harvard, in Boston, USA, in addition with participation of researchers from Dana Farber Cancer Institute, Massachusetts General Hospital, Medical School of Harvard University and Institute of Breast Diseases FUCAM, AC, Mexico City.

Dr. Alfredo Hidalgo,  INMEGEN Medical SciencesResearcher  in coordination with other researchers of this Institute, presented the results obtained by comparing the genome sequence of breast cancer against the genome of normal tissue of each patient. In addition to the sequencing data, the project analyzed patterns of alterations in DNA copy number and expression profiles of RNA which were analyzed by using various types of microarrays.

A total of 116 tumor samples were analyzed, over half of them were from Mexican patients,  ​​possible by participation of Institute of Breast Diseases FUCAM, AC

Among the most notable work results it is include the creation of  genes catalog which most frequently suffer mutation in breast tumors. It also could be assessed for the first time in Mexico the prevalence of different subtypes of breast tumors and finally, it was could identify the presence of alterations in a large number of genes, which have important clinical implications.

The results of this work constitute the first Mexico and Slim Genomic Medicine Initiative contribution ti the International Cancer Genome Consortium and one of the greatest efforts in regard to genome sequencing analysis of breast cancer worldwide . Their results enable a more complete picture about this important genomic alterations in tumor.

For more information on this project, please consult

Both comments and pings are currently closed.

Comments are closed.